Opioids for Cancer Pain: Pursuing Balance
Originally presented at HOPA's 13th Annual Conference, March 2017.
Recent public health concerns have arisen concerning the use of prescription opioids in the United States. Although they are mostly focused on nonmalignant pain, oncology practitioners should be aware of these issues and how they may affect their own practice. We will discuss potential strategies for appropriate opioid use in the cancer pain population.
- Review recent guidelines for opioid use in both nonmalignant and malignant pain populations.
- Discuss risk assessment tools for monitoring patients on opioids.
- Review data on long-term benefits and risks of opioid use.
Julie Waldfogel, PharmD CPE
Julie Waldfogel is a clinical pharmacy specialist in pain management and palliative care at the Johns Hopkins Hospital. She earned her PharmD degree from the University of Florida College of Pharmacy and completed a PGY-1 pharmacy practice residency with the North Florida/South Georgia VA Health System and a PGY-2 in pain and palliative care at the Johns Hopkins Hospital. She currently works in the palliative care service in the Sidney Kimmel Comprehensive Cancer Center.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020